The bill permanently schedules fentanyl analogues as Schedule I drugs under the Controlled Substances Act.
The Jha brothers admitted selling counterfeit Keytruda and other prescription drugs to undercover agents.
PSM is soliciting feedback on draft best practices until June 20th. Please review the guidelines and send your thoughts to editors@safemedicines.org.
The FDA warned companies over the sale of an unapproved medical device and contaminated eye medicines, and disbarred a Texan who sold illegally imported pharmaceuticals.
The FDA has announced a voluntary nationwide recall of two dietary supplements sold exclusively online by www.umary-usa.com. Lab testing revealed that Unavy Ácido HIALURÓNICO and Umovy Ácido HIALURÓNICO contain undeclared active pharmaceutical ingredients: diclofenac, dexamethasone, and omeprazole.
Federally-registered compounding facilities stopped making tirzepatide on May 22. This transition is significant for patients, and we at PSM think there are four things you should be watching for.
Operation RapTor led to 270 arrests and the seizure of more than $200 million in currency and digital assets.
Articles in Endpoints News and the Houston Chronicle raise questions about the regulatory process for 503B compounding facilities.
Exposes in the Houston Chronicle and Endpoints News examined Empower Pharmacy’s safety record. A grand jury indicted a Chinese company and three of its employees for pill press and counterfeit die mold sales.
The FDA wants to ensure that domestic and foreign companies receive the same level of regulatory oversight.
Catch up on research PSM released about medicines imported from unregistered sources.